Sagamicin1 '3) is a new aminoglycoside
antibiotic produced by Micromonospora sagainiensis. The antibiotic exhibits a potent antibacterial activity against a broad range of Gram-positive and Gramnegative bacteria. Its structure has been characterized as 6'-N-methylgentamicin C1a 3) (Fig. 1) . The structural differences of sagamicin from gentamicin C occur at the 6'-position ( Fig. 1 ). Several In the present investigation, the authors attempted to study the biosynthetic pathways for sagamicin and gentamicin more precisely. A number of blocked mutants were developed from :lf. sagamiensis and the intermediates produced by these mutants were isolated and characterized. Utilizing these blocked mutants and the intermediates isolated, biotransformation experiments were performed. In this paper, the authors report the isolation and characterization of the mutants blocked in the gentamicin C1 production. Biotransformation activities in the resting cells of the mutants were compared with those of a 2-deoxystreptamine (DOS) idiotroph, and the blocked step in sagamicin and gentamicin biosynthesis is proposed in each mutant. Based on these results, sagamicin biosynthesis in M. sagainiensis is discussed. 
Microorganisms
A sagamicin producing strain of Micromonospora sagamiensis, KY 11510, and a DOS idiotroph, KY 115258) were used.
Media
The seed and fermentation media of the following compositions were used. The seed medium; 2% Stabilose K (soluble starch), 0.5 % glucose, 0.5 % peptone, 0.5 % yeast extract, 0.3 % meat extract, and 0.2 % calcium carbonate (pH 8.0). The fermentation medium; 4 % Stabilose K, 1 % soy bean meal, 2 % Pharmamedia (cottonseed flour), 0.1 % corn oil, 0.5% casein, 0.2% phytate (1 Ca, 2Mg), 0.015% FeSO4 • 7H2O, 0.05 % MgSO4 7H2O and 0.025 KH2PO4 (pH 8.0).
Culture Condition First seed culture was developed in a large test tube (2.5 x 19 cm) containing 10 ml of the seed medium by shaking at 30°C for 3 days. One milliliter of the seed culture was transferred into a large test tube containing the seed medium and incubated for I day. Five milliliters of the second seed culture was transferred into a 300-ml flask containing 50 ml of the fermentation medium. The flask was in-VOL. XXXV NO. 1 cubated with shaking at 220 rpm at 30°C.
Biotransformation with Resting Cells
The mycelia grown in the fermentation medium for three days were washed three times with 0.1 M tris-HC1 buffer (pH 7.5). The washed mycelia were suspended in the same buffer and used for the biotransformation experiments. The reaction mixture, containing 150 mg (dry weight) of the washed cells and 500 jig of each substrate compound in 10 ml of 0.1 M tris-HCI buffer (pH 7.5), was incubated at 30°C for 20 hours with shaking.
Detection of Products
The reaction mixture or fermentation broth was acidified to pH 2.0 with oxalic acid and stirred at 30`C for 1 hour. After centrifugation, the supernatant was neutralized with aqueous ammonia, and applied to Amberlite IRC-50 ion-exchange resin (NH4+ form) column. The antibiotic was eluted with 2 N ammonium hydroxide, and the eluate was evaporated to dryness. The dried material was dissolved in distilled water to a desired concentration.
The products were detected by means of carbon10) and silica gel thin-layer chromatography (TLC) and paper chromatography using the following solvent system: the lower phase of chloroform -methanol -concentrated ammonium hydroxide (I : 1: 1, v/v) for silica gel TLC, 2: 1: 1 (v/v) (17%, ammonium hydroxide) for paper chromatography and 0.5 N hydrochloric acid -methanol (20: 1, v/v) for carbon TLC. Antibiotic zones on the chromatograms were detected by bioautography against Bacillus suhtilis ATCC 6633. Silica gel TLC was also visualized following RYOON-SMITH reaction.
The amount of the individual product was determined by in-situ fluorometric measurements of the 4-chloro-7-nitrobenzo-2-oxa-l,3-diazole derivatives formed on silica gel TLC plates.11)
Isolation of Fermentation Products
The fermentation broth was acidified to pH 2.0 with sulfuric acid and stirred for 1 hour at 60 C. After filtration, the filtrate was applied to Diaion HPK-25 resin (NH4+) column and eluted with 2 N ammonium hydroxide. The eluate was neutralized with 0.5 N hydrochloric acid and applied to Amberlite CG-50 resin (NH.,+) column. The resin was washed with distilled water and eluted with a linear gradient of 0.05 to 0.5 N ammonium hydroxide. Fractions were monitored using silica gel TLC or paper chromatography.
Similar fractions were combined, evaporated under reduced pressure to a small volume and lyophilized to yield crude preparations. Each preparation was further chromatographed on silica gel (Wako gel C-200) column. Antibiotic G-418 and gentamicin X2 were eluted with n-butanolethanol-conc. ammonium hydroxide (8: 10: 7, v/v), and sagamicin and gentamicins C1a C2 and C1 with the lower phase of chloroform -methanol -cone. ammonium hydroxide (3: 1: 1, v/v). Carbon column chromatography was also used for the separation of gentamicin C2 from C2a,12).
The antibiotics isolated were identified from the biological properties, chromatographic behavior, and mass and proton NMR spectra. Those properties of the antibiotics (gentamicin X. and antibiotic G-418 isolated from KY 11565, gentamicin Cla, C2a and sagamicin from KY 11564, and gentarnicin C._,;, and C1a from KT 11566) were each identical to the authentic samples'3-5,7,12,13> Materials Gentamicins A, A2 and X2, and antibiotics JI-20A, JI-20B and G-418 used for the biotransformation experiments were isolated from the cultured broth of M. sagamiensis mutant KY 11529 by chromatographic procedures14). Sagamicin and gentamicins C1a, C2, and C1 used for the biotransformation experiments were isolated from a culture broth of KY 11510 by the method described above. Authentic gentamicins were kindly supplied from Dr. G. H. WAGMAN of the Schering Corporation. 1982 sagamicin was dependent on the concentration of the cells (Fig. 3-a) and gentamicin C1a (Fig. 3-b) .
Sagamicin formation from gentamicin C1a, was markedly stimulated by S-adenosyl-L-methionine (Fig. 4) .
Addition of cobalt chloride (100 and 1000 ;'g/liter) did not affect sagamicin formation. Reaction mixture containing 500 jig of gentamicin C1a, sulfate and the increasing concentration of mycelia (mg dry weight/nil) in 10 ml of 0.1 M tris-HCI buffer (pH 7.5) was incubated at 30°C for 20 hours. b) Effect of gentamicin C1a, concentration on sagamicin formation.
Reaction mixture containing 113 mg of washed mycelia and the increasing amount of gentamicin C1a sulfate in 10 ml of 0.1 M tris-HCI buffer (pH 7.5) was incubated at 30°C for 20 hours.
Cell concentration (my/ml) Gentamicin C1 a g / ml; s-Adenosyl-L-sethionine (;mole/ml The reaction mixture containing 1000 pg (DOS, paronmmine or gentamicin A) or 500 jig (other compounds) of substrate and 113 rug of washed mycelia in 10 nil of 0.1 M tris-HCl buffer (pH 7.5) was incubated at 30°C for 20 hours. The results of the biotransformation of various gentamicin components in this system are summarized in Table 1 . DOS, paromamine, gentamicin A or X2 was transformed to C1a, C2, C1 and sagamicin; G-418 or JI-20B to C2 and C1; C2 to C1; JI-20A to C1a and sagamicin; C1a to sagamicin. The biotransformation activities from the presumed early intermediates (DOS, paromamine, gentamicin A or X2) to gentamicin C1a and sagamicin were higher than the activities to gentamicins C2 and C1.
Gentamicin C1 and sagamicin were not transformed to any detectable antibiotics. These results were in agreement with those from the growing cells of M. piapurea8) although the transformation activities from the early intermediates in M. pu purea were higher to gentamicins C2, and C1 than to sagamicin.
The Mutants Blocked in Gentamicin C1 Pathway M. sagarniensis KY 11510 co-produced gentamicin C1 with sagamicin in the fermentation. When KY 11510 was cultivated in the fermentation medium supplemented with cobalt chloride (1 mg/liter), the amount of gentamicin C1 production exceeded that of sagamicin' 2. The mutants which produced no gentamicin C1 in the cobalt supplemented medium were selected from NTG-treated population of KY 1151015). A variety of mutants blocked in gentamicin C1 pathway were isolated. Fermentation products by these mutants are shown in Table 2 . These products were isolated by the method described in "Materials and Methods", and identified on the basis of the chromatographic behavior, biological properties, and mass and proton NMR spectral analysis. Mutant KY 11538 produced sagamicin, but did not produce gentamicins C1, C2 and C2a even in the presence of cobalt's . KY 11565 produced gentamicin X. and antibiotic G-418. Addition of cobalt ion was found to have a significant effect upon the titer of both antibiotics without affecting the growth of the mutant. In the absence of cobalt ion, KY 11565 produced 240 jig/nil of gentamicin X2 and 122 ,ag/ml of G-418. Addition of 100 «g/liter of cobalt chloride resulted in a 2-fold decrease of gentamicin X2 and a 1.6-fold increase of G-418 (Fig. 5) . KY 11564 produced sagamicin, gentamicins C1a and C2a (6'-C-epimer of gentamicin C2) but did not produce gentamicin C2 or C1. Gentamicin C2a, was clearly differentiated from gentamicin C. by carbon TLC12). KY 11566 produced gentamicins C1a and C2a. A small amount (below 10% of C2a) of gentamicins C2, C1 and sagamicin were also detected. Cobalt ion affected the production of these antibiotics (Table 3) . Table 4 , gentamicin C2a was transformed to C2 and C1, and gentamicin C2 to C2a, and C1. The transformation activity from C2a to C2 was much higher than that from C2 to C2a. Both activities were completely abolished by heating the mycelium at 100°C for 5 minutes. Antibiotic JI-20B was transformed into gentamicins C2a, C2 and C1.
Biotransformation with the Resting Cells of the Blocked Mutants
The biotransformation of gentamicin components was performed with the resting cells of the blocked mutants (Table 5) . KY 11565, the producer of gentamicin X2 and G-418, transformed JI-20A
to gentamicin C1a, and sagamicin, JI-20B to gentamicins C2 and C1; gentamicin C1a to sagamicin; gentamicin C2a, to C1; and gentamicin C2, to C1. But the mutant lacked the activity to transform gentamicin A, X2 or G-418 to gentamicin C's or sagamicin.
The results suggest that the blockage in amino substitution activities at C-6' of both gentamicin X2 and G-418 (
Step 5 in Fig. 6 ) in KY 11565 resulted in the The mutants were cultivated in the fermentation medium in the presence (CoCl2+) or in the absence (CoCl2-) of 1 mg/liter of cobalt chloride at 30°C for 8 clays. Incubated at 30°C for 20 hours. But it possessed a weak activity for transformation of gentamicin C1a to sagamicin, and gentamicin C2 to C,. From these results, KY 11566 appears to be partially blocked in 6'-N-methylation activity (
Step 8 in Fig. 6 ). Gentamicin C2a
Gentamicin C2 ND; not detected, NT; not tested.
Discussion
Based on the results of the biotransformations and the intermediates produced by the blocked mutants, sagamicin biosynthetic pathway in M. sagamiensis is proposed as shown in Fig. 6 . Four kinds of blocked mutants including those blocked in the 6'-C-methylation step15) were obtained by selecting the non-gentamicin C1-producing mutants. Two mutants, KY 11565 and KY 11566, were blocked in sagamicin production as well as in gentamicin C, production.
KY 11565 appeared to have a blockage in 6'-amino substitution of gentamicin X2 and G-418, and KY 11566 in 6'-N-methylation of gentamicins C1a and C2. The results suggest that the 6'-amino substitution and the 6'-N-methylation, involved in both sagamicin and gentamicin C, synthesis are each catalized by a single enzyme.
Similarly, a single enzyme may be involved in the 3',4'-dehydroxylation (Step 6), but no mutants blocked in the step have been isolated in M. sagamiensis. Involvement of gentamicin C2a in the gentamicin C1 pathway was demonstrated with KY 11564, which is blocked in the 6'-epimerization of gentamicin C2a. The parent strain, KY 11510, produced both gentamicin C2a and C2 in equal amounts. KY 11564 produced gentamicin C2,, sagamicin and gentamicin C1a. The mutant possessed no activity to transform gentamicin C2a to C2. Utilizing a DOS idiotroph, KY 11525, it was demonstrated that the 6'-C epimerization step was reversible. In our biotransformation experiments, the presumed early intermediates were not isolated: paro- Further investigation may be required to verify other intermediates in the early steps of the proposed pathway (Fig. 6) .
Cobalt ion was shown to have a significant effect on the production of gentamicin X2 and G-418 in KY 11565. TESTA and TiLLEY16)r found that the C-methylation at the 6'-position and the 4"-position (step 3 and 4 in Fig. 6 ) depended on cobalt ion in M. purpur'a. The increase in the production of G-418, accompanying the decrease in gentamicin X2, in KY 11565 may be due to the stimulation of one oft he cobalt-dependent steps ( Step 4 in Fig. 6 ). Sagamicin production in the mutants blocked in step 4 was significantly stimulated by the addition of cobalt15). Activation of 4''-C-methylation by cobalt may lead to the stimulation of sagamicin production in the mutants. Cobalt ion did not affect the conversion activity from gentamicin C1a to sagamicin.
These results strongly support that the cobalt-dependent steps involved in the C-methylations, but not in the N-methylation. S-Aderosyl-L-methionine significantly stimulated the conversion from gentamicin C1a to sagamicin in the resting cells of KY 11525. DEGUCHt et nil.' reported that S-adenosyl-L-methionine-[methyl-14C] was incorporated into sagamicin at a low efficiency (4%) It may be suggested that methyl donor for the 6'-N-methylation is S-adenosyl-L-methionine.
